<?xml version="1.0" encoding="UTF-8"?>
<p id="Par96">The trial will be conducted with permission and in accordance with Queensland Health regulations on the use of medical cannabis and subject to approval and monitoring by each clinical site’s HREC [
 <xref ref-type="bibr" rid="CR4">4</xref>, 
 <xref ref-type="bibr" rid="CR22">22</xref>]. An independent DSMB to include a statistician, clinical pharmacologist, palliative care specialist and consumers will be formed and will meet regularly, with primary responsibility for monitoring adverse and serious adverse events. All AE’s and SAE’s will be reviewed at a minimum of 6 monthly intervals, or more frequently if needed.
</p>
